Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAN1012 in Pre-malignant Ductal Carcinoma in Situ and Lobular Carcinoma in Situ
NCT07408856Phase 1Recruiting
- Start
- Sep 2026
- Primary completion
- May 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of CAN1012 in ductal carcinoma in situ (DCIS) and lobular carcinoma in situ (LCIS) (4 arms). Primary endpoint: Safety of CAN1012. Started Sep 2026; status: recruiting.
02
Drugs
CAN1012
03
Conditions
ductal carcinoma in situ (DCIS)lobular carcinoma in situ (LCIS)
Beyond the preview
Go deeper on NCT07408856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07408856.